{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T17:01:53Z","timestamp":1788454913603,"version":"build-2803163510"},"reference-count":29,"publisher":"Elsevier BV","issue":"47","license":[{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2013,11,1]],"date-time":"2013-11-01T00:00:00Z","timestamp":1383264000000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000865","name":"Bill and Melinda Gates Foundation","doi-asserted-by":"crossref","id":[{"id":"10.13039\/100000865","id-type":"DOI","asserted-by":"crossref"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Vaccine"],"published-print":{"date-parts":[[2013,11]]},"DOI":"10.1016\/j.vaccine.2013.09.021","type":"journal-article","created":{"date-parts":[[2013,9,21]],"date-time":"2013-09-21T17:28:39Z","timestamp":1379784519000},"page":"5531-5536","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":33,"title":["Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults"],"prefix":"10.1016","volume":"31","author":[{"given":"Pauline","family":"Verdijk","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nynke Y.","family":"Rots","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique G.C.T.","family":"van Oijen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M. Steven","family":"Oberste","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Claire J.","family":"Boog","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiromasa","family":"Okayasu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roland W.","family":"Sutter","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wilfried A.M.","family":"Bakker","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.vaccine.2013.09.021_bib0005","unstructured":"Global eradication of poliomyelitis by the year 2000. Forty-first World Health Assembly, WHA41.281988."},{"key":"10.1016\/j.vaccine.2013.09.021_bib0010","doi-asserted-by":"crossref","first-page":"1023","DOI":"10.1111\/j.1749-6632.1955.tb42563.x","article-title":"A concept of the mechanism of immunity for preventing paralysis in poliomyelitis","volume":"61","author":"Salk","year":"1955","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0015","doi-asserted-by":"crossref","first-page":"575","DOI":"10.2105\/AJPH.45.5_Pt_1.575","article-title":"Vaccination against paralytic poliomyelitis performance and prospects","volume":"45","author":"Salk","year":"1955","journal-title":"Am J Public Health Nations Health"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0020","doi-asserted-by":"crossref","first-page":"899","DOI":"10.1586\/erv.09.49","article-title":"Future of polio vaccines","volume":"8","author":"Ehrenfeld","year":"2009","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0025","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1093\/infdis\/151.3.420","article-title":"Oral poliovirus vaccine: history of its development and use and current challenge to eliminate poliomyelitis from the world","volume":"151","author":"Sabin","year":"1985","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0030","doi-asserted-by":"crossref","first-page":"5","DOI":"10.1586\/14760584.8.1.5","article-title":"Role of injectable and oral polio vaccines in polio eradication","volume":"8","author":"John","year":"2009","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0035","doi-asserted-by":"crossref","first-page":"1150","DOI":"10.1126\/science.1130388","article-title":"New strategies for the elimination of polio from India","volume":"314","author":"Grassly","year":"2006","journal-title":"Science"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0040","doi-asserted-by":"crossref","first-page":"103","DOI":"10.1016\/j.biologicals.2006.02.007","article-title":"Vaccine-derived polioviruses","volume":"34","author":"Agol","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0045","doi-asserted-by":"crossref","first-page":"587","DOI":"10.1146\/annurev.micro.58.030603.123625","article-title":"Vaccine-derived polioviruses and the endgame strategy for global polio eradication","volume":"59","author":"Kew","year":"2005","journal-title":"Annu Rev Microbiol"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0050","first-page":"1","article-title":"Meeting of the strategic advisory group of experts on immunization, november 2012 \u2013 conclusions and recommendations","volume":"88","author":"Meeting","year":"2013","journal-title":"Wkly Epidemiol Rec"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0055","doi-asserted-by":"crossref","first-page":"2649","DOI":"10.1016\/j.vaccine.2009.02.071","article-title":"Vaccine-derived poliovirus (VDPV): impact on poliomyelitis eradication","volume":"27","author":"Minor","year":"2009","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0060","doi-asserted-by":"crossref","first-page":"1587","DOI":"10.1086\/593310","article-title":"New generation of inactivated poliovirus vaccines for universal immunization after eradication of poliomyelitis","volume":"47","author":"Chumakov","year":"2008","journal-title":"Clin Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0065","doi-asserted-by":"crossref","first-page":"6943","DOI":"10.1016\/j.vaccine.2010.08.023","article-title":"Polio vaccines and polio immunization in the pre-eradication era: WHO position paper \u2013 recommendations","volume":"28","author":"Polio","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0070","doi-asserted-by":"crossref","first-page":"3778","DOI":"10.1016\/j.vaccine.2010.02.095","article-title":"The global introduction of inactivated polio vaccine can circumvent the oral polio vaccine paradox","volume":"28","author":"Heinsbroek","year":"2010","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0075","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.biologicals.2006.02.011","article-title":"Technology transfer of Sabin-IPV to new developing country markets","volume":"34","author":"Kreeftenberg","year":"2006","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0080","doi-asserted-by":"crossref","first-page":"635","DOI":"10.1586\/erv.11.51","article-title":"Clinical development of a novel inactivated poliomyelitis vaccine based on attenuated Sabin poliovirus strains","volume":"10","author":"Verdijk","year":"2011","journal-title":"Expert Rev Vacc"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0085","first-page":"163","article-title":"Progress with inactivated poliovirus vaccines derived from the Sabin strains","volume":"105","author":"Doi","year":"2001","journal-title":"Dev Biol (Basel)"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0090","doi-asserted-by":"crossref","DOI":"10.1093\/infdis\/jit155","article-title":"Phase II and III clinical studies of diphtheria\u2013tetanus\u2013acellular pertussis vaccine containing inactivated polio vaccine derived from sabin strains (DTaP-sIPV)","author":"Okada","year":"2013","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0095","series-title":"Purified pertussis diptheria tetanus inactivated poliomyelitis (sabin strain) combined vaccine. Notice of marketing authorization approval","author":"Adsorbed","year":"2012"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0100","doi-asserted-by":"crossref","first-page":"237","DOI":"10.1093\/infdis\/jir723","article-title":"Safety and immunogenicity of inactivated poliovirus vaccine made from Sabin strains: a phase II, randomized, positive-controlled trial","volume":"205","author":"Liao","year":"2012","journal-title":"J Infect Dis"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0105","doi-asserted-by":"crossref","first-page":"1441","DOI":"10.1111\/j.1539-6924.2006.00840.x","article-title":"Risk management in a polio-free world","volume":"26","author":"Aylward","year":"2006","journal-title":"Risk Anal"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0110","doi-asserted-by":"crossref","first-page":"699","DOI":"10.1038\/434699a","article-title":"A global call for new polio vaccines","volume":"434","author":"Heymann","year":"2005","journal-title":"Nature"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0115","doi-asserted-by":"crossref","first-page":"7188","DOI":"10.1016\/j.vaccine.2011.05.079","article-title":"Inactivated polio vaccine development for technology transfer using attenuated Sabin poliovirus strains to shift from Salk-IPV to Sabin-IPV","volume":"29","author":"Bakker","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0120","first-page":"119","article-title":"Potency testing of killed polio vaccine in rats","volume":"47","author":"van Steenis","year":"1981","journal-title":"Dev Biol Stand"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0125","doi-asserted-by":"crossref","first-page":"301","DOI":"10.1006\/biol.1995.0049","article-title":"A WHO collaborative study of immunogenicity assays of inactivated poliovirus vaccines","volume":"23","author":"Wood","year":"1995","journal-title":"Biologicals"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0130","doi-asserted-by":"crossref","first-page":"3390","DOI":"10.1016\/j.vaccine.2011.02.085","article-title":"Characterization and standardization of Sabin based inactivated polio vaccine: proposal for a new antigen unit for inactivated polio vaccines","volume":"29","author":"Westdijk","year":"2011","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0135","doi-asserted-by":"crossref","first-page":"1298","DOI":"10.1016\/j.vaccine.2012.12.076","article-title":"Antigen sparing with adjuvanted inactivated polio vaccine based on Sabin strains","volume":"31","author":"Westdijk","year":"2013","journal-title":"Vaccine"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0140","doi-asserted-by":"crossref","first-page":"760","DOI":"10.1097\/00006454-198811000-00003","article-title":"Sabin inactivated trivalent poliovirus vaccine: first clinical trial and seroimmunity survey","volume":"7","author":"Murph","year":"1988","journal-title":"Pediatr Infect Dis J"},{"key":"10.1016\/j.vaccine.2013.09.021_bib0145","first-page":"341","article-title":"Problems of prevention and control of poliomyelitis in Poland","volume":"64","author":"Mazurowska-Magdzik","year":"2010","journal-title":"Przegl Epidemiol"}],"container-title":["Vaccine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012528?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0264410X13012528?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,2]],"date-time":"2025-10-02T10:19:59Z","timestamp":1759400399000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0264410X13012528"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2013,11]]},"references-count":29,"journal-issue":{"issue":"47","published-print":{"date-parts":[[2013,11]]}},"alternative-id":["S0264410X13012528"],"URL":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.021","relation":{},"ISSN":["0264-410X"],"issn-type":[{"value":"0264-410X","type":"print"}],"subject":[],"published":{"date-parts":[[2013,11]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Safety and immunogenicity of inactivated poliovirus vaccine based on Sabin strains with and without aluminum hydroxide: A phase I trial in healthy adults","name":"articletitle","label":"Article Title"},{"value":"Vaccine","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.vaccine.2013.09.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2013 Elsevier Ltd. Published by Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}